Koers ISIS Pharmaceuticals, Inc. Nasdaq
Aandelen
US4643301090
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 620 mln. 581 mln. | Omzet 2025 * | 777 mln. 729 mln. | Marktkapitalisatie | 6,02 mld. 5,65 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -568 mln. -533 mln. | Nettowinst (verlies) 2025 * | -493 mln. -463 mln. | EV/omzet 2024 * | 9,53 x |
Nettoliquiditeiten 2024 * | 111 mln. 104 mln. | Nettoschuld 2025 * | 218 mln. 205 mln. | EV/omzet 2025 * | 8,03 x |
K/w-verhouding 2024 * |
-10,5
x | K/w-verhouding 2025 * |
-12,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,13% |
Recentste transcriptie over ISIS Pharmaceuticals, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 01-07-12 |
Brett Monia
FOU | Founder | 62 | 10-01-89 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 01-05-00 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 03-02-14 |
Brett Monia
FOU | Founder | 62 | 10-01-89 |
Joan Herman
BRD | Director/Board Member | 70 | 10-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |